Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Core Insights - Rhythm Pharmaceuticals, Inc. (RYTM) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with a consensus outlook indicating a quarterly loss of $0.72 per share, reflecting a +1.4% change from the previous year, and revenues projected at $50.24 million, up 51.1% from the year-ago quarter [1][3] Earnings Expectations - The earnings report is anticipated to be released on November 4, and if the actual results exceed expectations, the stock may experience upward movement; conversely, a miss could lead to a decline [2] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Rhythm Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +9.24%, indicating a bullish sentiment among analysts [11] - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [9] Historical Performance - In the last reported quarter, Rhythm Pharmaceuticals was expected to post a loss of $0.66 per share but actually reported a loss of -$0.75, resulting in a surprise of -13.64% [12] - Over the past four quarters, the company has only beaten consensus EPS estimates once [13] Conclusion - Rhythm Pharmaceuticals is viewed as a compelling candidate for an earnings beat, but investors should consider other factors influencing stock performance beyond just earnings results [16]